Proactive Investors - Run By Investors For Investors

Humanigen new research shows encouraging results for cancer treatment using Car-T

Humanigen (OTCMKTS:HGEN) CEO Cameron Durrant joined Steve Darling from Proactive Investors in Los Angeles at the LD Micro show to provide details about their latest research regarding the use of Car-T therapy in the treatment of certain blood cancers. That research was just published in the digital version if Blood Magazine. 

View full HGEN profile View Profile

Humanigen Inc Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use